Cancers (Sep 2023)

Penile-Sparing Surgery for Tumour Recurrence after Previous Glansectomy/Partial Penectomy: Treatment Feasibility and Oncological Outcomes

  • Gennaro Musi,
  • Filippo Molinari,
  • Francesco A. Mistretta,
  • Mattia Luca Piccinelli,
  • Sonia Guzzo,
  • Marco Tozzi,
  • Elena Lievore,
  • Oskar Blezien,
  • Matteo Fontana,
  • Antonio Cioffi,
  • Daniela Cullurà,
  • Elena Verri,
  • Maria Cossu Rocca,
  • Franco Nolè,
  • Matteo Ferro,
  • Ottavio de Cobelli,
  • Stefano Luzzago

DOI
https://doi.org/10.3390/cancers15194807
Journal volume & issue
Vol. 15, no. 19
p. 4807

Abstract

Read online

We tested the feasibility and oncological outcomes after penile-sparing surgery (PSS) for local recurrent penile cancer after a previous glansectomy/partial penectomy. We retrospectively analysed 13 patients (1997–2022) with local recurrence of penile cancer after a previous glansectomy or partial penectomy. All patients underwent PSS: circumcision, excision, or laser ablation. First, technical feasibility, treatment setting, and complications (Clavien–Dindo) were recorded. Second, Kaplan–Meier plots depicted overall and local recurrences over time. Overall, 11 (84.5%) vs. 2 (15.5%) patients were previously treated with glansectomy vs. partial penectomy. The median (IQR) time to disease recurrence was 56 (13–88) months. Six (46%) vs. two (15.5%) vs. five (38.5%) patients were treated with, respectively, local excision vs. local excision + circumcision vs. laser ablation. All procedures, except one, were performed in an outpatient setting. Only one Clavien–Dindo 2 complication was recorded. The median follow-up time was 41 months. Overall, three (23%) vs. four (30.5%) patients experienced local vs. overall recurrence, respectively. All local recurrences were safely treated with salvage surgery. In conclusion, we reported the results of a preliminary analysis testing safety, feasibility, and early oncological outcomes of PSS procedures for patients with local recurrence after previous glansectomy or partial penectomy. Stronger oncological outcomes should be tested in other series to optimise patient selection.

Keywords